This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hajjeh, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hajjeh, R. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3242-3244, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

M. A. Pfaller,1,* S. A. Messer,1 R. J. Hollis,1 R. N. Jones,1 G. V. Doern,1 M. E. Brandt,2 and R. A. Hajjeh2

Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa,1 and Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia2

Received 16 July 1998/Returned for modification 21 August 1998/Accepted 15 September 1998

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

BMS-207147, Sch 56592, and voriconazole are three new investigational triazoles with broad-spectrum antifungal activity. The in vitro activities of these three agents were compared with those of itraconazole and fluconazole against 1,300 bloodstream isolates of Candida species obtained from over 50 different medical centers in the United States. The MICs of all of the antifungal drugs were determined by broth microdilution tests performed according to the National Committee for Clinical Laboratory Standards method using RPMI 1640 as a test medium. BMS-207147, Sch 56592, and voriconazole were all quite active against all Candida sp. isolates (MICs for 90% of the isolates tested [MIC90s], 0.5, 1.0, and 0.5 µg/ml, respectively). Candida albicans was the most susceptible species (MIC90s, 0.03, 0.06, and 0.06 µg/ml, respectively), and C. glabrata was the least susceptible (MIC90s, 4.0, 4.0, and 2.0 µg/ml, respectively). BMS-207147, Sch 56592, and voriconazole were all more active than itraconazole and fluconazole against C. albicans, C. parapsilosis, C. tropicalis, and C. krusei. There existed a clear rank order of in vitro activity of the five azoles examined in this study when they were tested versus C. glabrata: voriconazole > BMS-207147 = Sch 56592 = itraconazole > fluconazole (MIC90s, 2.0, 4.0, 4.0, 4.0, and 64 µg/ml, respectively). For isolates of Candida spp. with decreased susceptibility to both itraconazole and fluconazole, the MICs of BMS-207147, Sch 56592, and voriconazole were also elevated. These results suggest that BMS-207147, Sch 56592, and voriconazole all possess promising antifungal activity and that further in vitro and in vivo investigations are warranted to establish the clinical value of this improved potency.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

BMS-207147, Sch 56592, and voriconazole are all investigational triazole antifungal agents that are in different stages of in vitro and clinical investigation (2, 3, 7). Previous in vitro studies of these agents indicate a spectrum of antifungal activity broader than that of fluconazole (1-4, 6, 7, 10, 11). All three investigational triazoles are lipophilic and exhibit activity similar to that of itraconazole against clinically important yeast isolates (2, 3, 7). However, earlier investigations have included limited numbers of clinical yeast isolates and have compared each of these new agents individually against fluconazole and itraconazole. None of the previously published reports have compared all three investigational triazoles simultaneously against a large (>1,000 isolates) collection of recent, clinically important Candida isolates. In this study, we compare the in vitro activities of BMS-207147, Sch 56592, and voriconazole with those of fluconazole and itraconazole against 1,300 clinical isolates of Candida spp. from bloodstream infections. The in vitro antifungal susceptibility test method employed was the broth microdilution adaptation of the macrodilution reference method described in National Committee for Clinical Laboratory Standards (NCCLS) document M27-A (5).

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

Organisms. A total of 1,300 bloodstream isolates of Candida spp. obtained from over 50 U.S. medical centers between 1992 and 1997 were selected for testing. Approximately 550 isolates were obtained as part of a population-based survey of invasive mycoses conducted by the Centers for Disease Control and Prevention (8), and the remainder were from various medical centers throughout the United States. Included were C. albicans (660 isolates), C. parapsilosis (221 isolates), C. glabrata (217 isolates), C. tropicalis (139 isolates), C. krusei (33 isolates), and other Candida spp. (30 isolates, including 7 of C. lusitaniae, 7 of C. gulliermondii, 3 of C. famata, 2 of C. rugosa, 1 of C. lipolytica, 1 of C. lambica, and 9 of Candida unidentified to species level). All isolates were identified by standard methods (12) and stored as water suspensions at ambient temperature until used in the study. Prior to testing, each isolate was subcultured at least twice on potato dextrose agar plates (Remel, Lenexa, Kans.) to ensure purity and optimal growth.

Antifungal agents. Standard antifungal powders of BMS-207147 (Bristol-Myers Squibb), Sch 56592 (Schering-Plough), voriconazole (Pfizer), fluconazole (Pfizer), and itraconazole (Janssen) were obtained from their respective manufacturers. Stock solutions were prepared in dimethyl sulfoxide (BMS-207147 and voriconazole), polyethylene glycol (Sch 56592 and itraconazole), or water (fluconazole). Serial twofold dilutions of each antifungal agent were prepared exactly as outlined in NCCLS document M27-A (5). Final dilutions were made in RPMI 1640 medium (Sigma Chemical Co., St. Louis, Mo.) buffered to pH 7.0 with 0.165 M morpholinepropanesulfonic acid (MOPS) buffer (Sigma). The final concentration of the solvent did not exceed 1% in any well. Aliquots (0.1 ml) of each antifungal agent at a 2× final concentration were dispensed into the wells of plastic microdilution trays by using a Quick Spense II System (Dynatech Laboratories, Chantilly, Va.). The trays were sealed and frozen at -70°C until they were used.

Antifungal susceptibilities studies. Broth microdilution testing was performed in accordance with the guidelines in NCCLS document M27-A (5) by using the spectrophotometric method of inoculum preparation, an inoculum concentration of (1.5 ± 1.0) × 103 cells/ml, and RPMI 1640 medium buffered to pH 7.0 with MOPS. A 100-µl yeast inoculum was added to each well of the microdilution trays. The final concentrations of the antifungal agents were 0.008 to 8.0 µg/ml for BMS-207147, Sch 56592, voriconazole, and itraconazole and 0.12 to 128 µg/ml for fluconazole. The trays were incubated in air at 35°C, and MIC endpoints were read after 48 h of incubation. Drug-free and yeast-free controls were included.

Following incubation, the broth microdilution wells were examined with the aid of a reading mirror; the growth in each well was compared with that of the growth control (drug-free) well. The MIC of each triazole was defined as the lowest concentration resulting in 80% inhibition of growth compared to that for untreated controls (5). The data are reported as the concentrations of each antifungal agent necessary to inhibit 50% (MIC50) and 90% (MIC90) of the isolates tested.

Quality control. Quality was controlled by testing the following strains recommended by NCCLS document M27-A (5): C. parapsilosis ATCC 22019 and C. krusei ATCC 6258.

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

Table 1 summarizes the in vitro susceptibilities of 1,300 isolates of Candida spp. to BMS-207147, Sch 56592, voriconazole, fluconazole, and itraconazole. A broad range of MICs was observed with each antifungal agent. Overall, BMS-207147, Sch 56592, and voriconazole were quite active (MIC90s, 0.5, 1.0, and 0.5 µg/ml, respectively) against these isolates. C. albicans was the most susceptible species (MIC90s, 0.03, 0.06, and 0.06 µg/ml, respectively), and C. glabrata was the least susceptible (MIC90s, 4.0, 4.0, and 2.0 µg/ml, respectively) to the three investigational triazoles. BMS-207147, Sch 56592, and voriconazole were all more active than both itraconazole and fluconazole against C. albicans, C. parapsilosis, C. tropicalis, and C. krusei. Voriconazole was also more active than both itraconazole and fluconazole against C. glabrata (MIC90s, 2.0, 4.0, and 64 µg/ml, respectively). BMS-207147 and Sch 56592 were comparable to itraconazole (MIC90, 4.0 µg/ml) but more active than fluconazole against C. glabrata (MIC90, 4.0 versus 64 µg/ml).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   In vitro susceptibilities of 1,300 Candida bloodstream isolates to BMS-207147, Sch 56592, and voriconazole versus fluconazole and itraconazole

One hundred forty-six strains (121 of C. glabrata, 14 of C. krusei, 6 of C. parapsilosis, and 4 of C. albicans) were inhibited by 16- to 32-µg/ml fluconazole (dose-dependently susceptibility) (9). The MIC90s of each of the investigational triazoles ranged from 1.0 to 2.0 µg/ml for these isolates and were not significantly different from those observed for the overall isolate collection (data not shown).

Among the 1,300 isolates studied, a total of 53 strains (12 of C. albicans, 13 of C. krusei, 25 of C. glabrata, and 3 of C. tropicalis) were resistant to both fluconazole (MIC, >= 64 µg/ml) and itraconazole (MIC, >= 1 µg/ml) (9). The MICs of BMS-207147 (0.03 to >8.0 µg/ml; mode, >= 8.0 µg/ml), Sch 56592 (0.03 to >8.0 µg/ml; mode, >= 8.0 µg/ml), and voriconazole (0.25 to >16 µg/ml; mode, >= 16 µg/ml) were also elevated with these isolates (Table 2).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   In vitro activities of BMS-207147, Sch56592, and voriconazole against isolates of Candida species with decreased susceptibility to fluconazole and itraconazole

These results support and extend findings reported previously (2, 3, 7). We found that all three investigational triazoles were more active than fluconazole against all of the Candida spp. tested. In almost every case, the in vitro potencies of BMS-207147, Sch 56592, and voriconazole were comparable to one another and slightly greater than that of itraconazole. In contrast to the study of Fung-Tomc et al. (2), ours found BMS-207147 to be quite active against C. tropicalis and to have measurable activity against C. glabrata. Similar to the studies of Marco et al. (3) and of Pfaller et al. (7), ours found that those isolates of Candida spp. with decreased susceptibility to fluconazole and itraconazole were also less susceptible to the investigational triazoles, suggesting cross-resistance that is likely to be mediated by one or more efflux mechanisms (13).

In summary, we found that BMS-207147, Sch 56592, and voriconazole all exhibit excellent in vitro activity against clinically significant isolates of Candida spp. These agents are slightly more active than itraconazole and offer important advantages over fluconazole in terms of spectrum and potency. As always, the translation of this in vitro activity into clinical efficacy must be established. Further investigation of these exciting new agents is encouraged.

    ACKNOWLEDGMENTS

We thank Kay Meyer for secretarial assistance in the preparation of the manuscript and gratefully acknowledge the members of the Mycotic Diseases Active Surveillance Group: Gretchen Rothrock, Nicholas Czap, Pamala Daily, Lisa Gelling, Nanduni Mukerjee (California), and Laura Conn (CDC).

This study was partially supported by a grant from Bristol-Myers Squibb and by contributions from Pfizer Pharmaceuticals, the Schering-Plough Research Institute, and Janssen Pharmaceuticals.

    FOOTNOTES

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 394-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
References

1. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949[Abstract].
2. Fung-Tomc, J. C., E. Huczko, B. Minassian, and D. P. Bonner. 1998. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob. Agents Chemother. 42:313-318[Abstract/Free Full Text].
3. Marco, F., M. A. Pfaller, S. Messer, and R. N. Jones. 1998. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 42:161-163[Abstract/Free Full Text].
4. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698[Abstract].
5. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
6. Perfect, J. R., G. M. Cox, R. K. Dodge, and W. A. Schell. 1996. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother. 40:1910-1913[Abstract].
7. Pfaller, M. A., S. Messer, and R. N. Jones. 1997. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 41:233-235[Abstract].
8. Rees, J. R., R. W. Pinner, R. A. Hajjeh, M. E. Brandt, and A. L. Reingold. The epidemiologic features of invasive mycotic infections in the San Francisco Bay area 1992-1993: results of a population-based laboratory active surveillance. Clin. Infect. Dis., in press.
9. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry for The Subcommittee on Antifungal Susceptibility Testing of The National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247[Medline].
10. Ruhnke, M., A. Schmidt-Westhausen, and M. Trautmann. 1997. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:575-577[Abstract].
11. Sugar, A. M., and X.-P. Liu. 1996. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother. 40:1314-1316[Abstract].
12. Warren, N. G., and K. C. Hazen. 1995. Candida, Cryptococcus, and other yeasts of medical importance, p. 723-737. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.), Manual of clinical microbiology, 6th ed. American Society for Microbiology, Washington, D.C.
13. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402[Abstract/Free Full Text].

Antimicrobial Agents and Chemotherapy, December 1998, p. 3242-3244, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Karlsson, M. O., Lutsar, I., Milligan, P. A. (2009). Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies. Antimicrob. Agents Chemother. 53: 935-944 [Abstract] [Full Text]  
  • Morris, M. I. (2009). Posaconazole: A new oral antifungal agent with an expanded spectrum of activity. Am J Health Syst Pharm 66: 225-236 [Abstract] [Full Text]  
  • Trofa, D., Gacser, A., Nosanchuk, J. D. (2008). Candida parapsilosis, an Emerging Fungal Pathogen. Clin. Microbiol. Rev. 21: 606-625 [Abstract] [Full Text]  
  • Lortholary, O., Dannaoui, E., Raoux, D., Hoinard, D., Datry, A., Paugam, A., Poirot, J.-L., Lacroix, C., Dromer, F., the YEASTS Group, (2007). In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 51: 3378-3380 [Abstract] [Full Text]  
  • Seifert, H., Aurbach, U., Stefanik, D., Cornely, O. (2007). In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates. Antimicrob. Agents Chemother. 51: 1818-1821 [Abstract] [Full Text]  
  • Liu, P., Foster, G., LaBadie, R., Somoza, E., Sharma, A. (2007). Pharmacokinetic Interaction between Voriconazole and Methadone at Steady State in Patients on Methadone Therapy. Antimicrob. Agents Chemother. 51: 110-118 [Abstract] [Full Text]  
  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother. 50: 2009-2015 [Abstract] [Full Text]  
  • Messer, S. A., Jones, R. N., Fritsche, T. R. (2006). International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003).. J. Clin. Microbiol. 44: 1782-1787 [Abstract] [Full Text]  
  • Yan, J.-H., Marino, M. R., Smith, R. A., Kanamaluru, V., O'Mara, E. M., Grasela, D. M. (2006). The Effect of Ravuconazole on the Pharmacokinetics of Nelfinavir in Healthy Male Volunteers. J Clin Pharmacol 46: 193-200 [Abstract] [Full Text]  
  • Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55: 317-319 [Abstract] [Full Text]  
  • Gao, H., Pennesi, M. E., Shah, K., Qiao, X., Hariprasad, S. M., Mieler, W. F., Wu, S. M., Holz, E. R. (2004). Intravitreal Voriconazole: An Electroretinographic and Histopathologic Study. Arch Ophthalmol 122: 1687-1692 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J. (2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 48: 1188-1196 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Chryssanthou, E., Cuenca-Estrella, M. (2002). Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing Proposed Standard and the E-Test with the NCCLS Broth Microdilution Method for Voriconazole and Caspofungin Susceptibility Testing of Yeast Species. J. Clin. Microbiol. 40: 3841-3844 [Abstract] [Full Text]  
  • Venkataramanan, R., Zang, S., Gayowski, T., Singh, N. (2002). Voriconazole Inhibition of the Metabolism of Tacrolimus in a Liver Transplant Recipient and in Human Liver Microsomes. Antimicrob. Agents Chemother. 46: 3091-3093 [Abstract] [Full Text]  
  • Laverdiere, M., Hoban, D., Restieri, C., Habel, F. (2002). In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50: 119-123 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Diekema, D. J. (2002). In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 46: 1723-1727 [Abstract] [Full Text]  
  • PELLETIER, R., LORANGER, L., MARCOTTE, H., DE CAROLIS, E. (2002). Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 51: 479-483 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J. (2002). Clinical Evaluation of a Frozen Commercially Prepared Microdilution Panel for Antifungal Susceptibility Testing of Seven Antifungal Agents, Including the New Triazoles Posaconazole, Ravuconazole, and Voriconazole. J. Clin. Microbiol. 40: 1694-1697 [Abstract] [Full Text]  
  • Clemons, K. V., Martinez, M., Calderon, L., Stevens, D. A. (2002). Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis. Antimicrob. Agents Chemother. 46: 922-924 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., Hollis, R. J. (2002). Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Bloodstream Infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40: 852-856 [Abstract] [Full Text]  
  • Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., Donowitz, L. G. (2001). Fluconazole Prophylaxis against Fungal Colonization and Infection in Preterm Infants. NEJM 345: 1660-1666 [Abstract] [Full Text]  
  • Clemons, K. V., Stevens, D. A. (2001). Efficacy of Ravuconazole in Treatment of Mucosal Candidosis in SCID Mice. Antimicrob. Agents Chemother. 45: 3433-3436 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Mills, K., Bolmstrom, A., Jones, R. N. (2001). Evaluation of Etest Method for Determining Caspofungin (MK-0991) Susceptibilities of 726 Clinical Isolates of Candida Species. J. Clin. Microbiol. 39: 4387-4389 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Mills, K., Bolmstrom, A., Jones, R. N. (2001). Evaluation of Etest Method for Determining Posaconazole MICs for 314 Clinical Isolates of Candida Species. J. Clin. Microbiol. 39: 3952-3954 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N. (2001). In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans. Antimicrob. Agents Chemother. 45: 2862-2864 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., The SENTRY Participant Group, (2001). International Surveillance of Bloodstream Infections Due to Candida Species: Frequency of Occurrence and In Vitro Susceptibilities to Fluconazole, Ravuconazole, and Voriconazole of Isolates Collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39: 3254-3259 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., Walsh, T. J. (2001). Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. Antimicrob. Agents Chemother. 45: 857-869 [Abstract] [Full Text]  
  • Roberts, J., Schock, K., Marino, S., Andriole, V. T. (2000). Efficacies of Two New Antifungal Agents, the Triazole Ravuconazole and the Echinocandin LY-303366, in an Experimental Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 44: 3381-3388 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Houston, A., Mills, K., Bolmstrom, A., Jones, R. N. (2000). Evaluation of the Etest Method for Determining Voriconazole Susceptibilities of 312 Clinical Isolates of Candida Species by Using Three Different Agar Media. J. Clin. Microbiol. 38: 3715-3717 [Abstract] [Full Text]  
  • Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr., Moss, E. L. Jr., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G. H., Hare, R. S. (2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44: 2017-2022 [Abstract] [Full Text]  
  • Li, R.-K., Ciblak, M. A., Nordoff, N., Pasarell, L., Warnock, D. W., McGinnis, M. R. (2000). In Vitro Activities of Voriconazole, Itraconazole, and Amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum. Antimicrob. Agents Chemother. 44: 1734-1736 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Moore, C. B., Walls, C. M., Denning, D. W. (2000). In Vitro Activity of the New Triazole BMS-207147 against Aspergillus Species in Comparison with Itraconazole and Amphotericin B. Antimicrob. Agents Chemother. 44: 441-443 [Abstract] [Full Text]  
  • Diekema, D. J., Pfaller, M. A., Messer, S. A., Houston, A., Hollis, R. J., Doern, G. V., Jones, R. N., The SENTRY PARTICIPANTS GROUP, (1999). In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America. Antimicrob. Agents Chemother. 43: 2236-2239 [Abstract] [Full Text]  
  • Lozano-Chiu, M., Arikan, S., Paetznick, V. L., Anaissie, E. J., Rex, J. H. (1999). Optimizing Voriconazole Susceptibility Testing of Candida: Effects of Incubation Time, Endpoint Rule, Species of Candida, and Level of Fluconazole Susceptibility. J. Clin. Microbiol. 37: 2755-2759 [Abstract] [Full Text]  
  • Hoban, D. J., Zhanel, G. G., Karlowsky, J. A. (1999). In Vitro Susceptibilities of Candida and Cryptococcus neoformans Isolates from Blood Cultures of Neutropenic Patients. Antimicrob. Agents Chemother. 43: 1463-1464 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Gee, S., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., Soll, D. R. (1999). In Vitro Susceptibilities of Candida dubliniensis Isolates Tested against the New Triazole and Echinocandin Antifungal Agents. J. Clin. Microbiol. 37: 870-872 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hajjeh, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Hajjeh, R. A.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»